Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06193577

Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters

Evaluation of the efficacy of Phaseolus vulgaris L. dry extract on weight modulation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

A.O.U. Policlinico "G. Rodolico - San Marco"

Catania, 95123, Italy

Location status: Recruiting

Location contact

Carmelo Gusmano, MD

CONTACT

About this study

Monocentric, prospective, randomized, single-blind clinical trial to evaluate the effects of Phaseolus vulgaris L. dry extract (test) on weight reduction and on metabolic parameters after 12 weeks of supplementation. The efficacy on weight reduction will be evaluated in comparison with the placebo group (control).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subjects aged between 18 and 60 years
  • BMI between 25 and 35 kg/m2
  • Habitual consumption of three main meals a day
  • Stable body weight during the 3 months prior to enrollment
  • Commitment to adhere to the diet and avoid the use of other weight loss products during the study
  • Commitment not to change lifestyle significantly for the entire duration of the study.
  • Signing of informed consent

Exclusion criteria

  • Hypergonadotropic hypogonadism and hypogonadotropic hypogonadism
  • Diabetes mellitus
  • Smoking > 10 cigarettes/day
  • Alcohol > 2 alcohol units/day (equal to 24 g of ethanol)
  • History of eating disorders during the 12 months prior to enrollment
  • Use of any drug or product to treat obesity (e.g. meal replacements)
  • Presence of acute or chronic gastrointestinal diseases
  • Active use of drugs that could influence the functions: gastrointestinal (e.g. laxatives, etc.), insulin (insulin sensitizers, etc.) and/or testicular (hormones, substances that influece testosterone production
  • Known sensitivity to the ingredients of the preparation
  • Any other clinical condition judged by the investigator to be incompatible with participation in the trial

Treatment and study plan

Phaseolus Vulgaris L. Dry Extract

Dietary Supplement

Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.

Placebo

Dietary Supplement

The placebo control does not contain active ingredients.

Primary outcomes

  1. Change in weight

    Time frame: 0, 12 weeks

    Weight evaluation before and after treatment

Secondary outcomes

  1. Change in weight

    Time frame: 0, 4, 8, 18 weeks

    Weight evaluation before and after treatment

  2. Change in Body Mass Index

    Time frame: 0, 4, 8, 12, 18 weeks

    BMI evaluation before and after treatment

  3. Change in glycemia

    Time frame: 0, 4, 8, 12, 18 weeks

    Glycemia evaluation before and after treatment

  4. Change in total testosterone levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Total testosterone levels evaluation before and after treatment

  5. Change in LH levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Luteinizing hormone (LH) levels evaluation before and after treatment

  6. Change in FSH levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Follicle-stimulating hormone (FSH) levels evaluation before and after treatment

  7. Change in SHBG levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Sex Hormone Binding Globulin (SHBG) levels evaluation before and after treatment

  8. Change in 17-beta-estradiol levels

    Time frame: 0, 4, 8, 12, 18 weeks

    17-beta-estradiol levels evaluation before and after treatment

  9. Change in insulin levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Insulin levels evaluation before and after treatment

  10. Change in albumin levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Albumin levels evaluation before and after treatment

  11. Change in carboxylated osteocalcin (cxOCN) levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Carboxylated osteocalcin levels evaluation before and after treatment

  12. Change in uncarboxylated osteocalcin (ucOCN) levels

    Time frame: 0, 4, 8, 12, 18 weeks

    Uncarboxylated osteocalcin levels evaluation before and after treatment

  13. Change in calculated free testosterone (CFT) concentrations

    Time frame: 0, 4, 8, 12, 18 weeks

    Calculated free testosterone (CFT) concentrations evaluation before and after treatment

  14. Sperm count

    Time frame: 0, 12, 18 weeks

    Sperm count before and after treatment

  15. Sperm motility

    Time frame: 0, 12, 18 weeks

    Sperm motility before and after treatment

  16. Sperm morphology evaluation

    Time frame: 0, 12, 18 weeks

    Sperm morphology evaluation before and after treatment

  17. Sperm vitality

    Time frame: 0, 12, 18 weeks

    Sperm vitality evaluation before and after treatment

  18. Tunel test

    Time frame: 0, 12, 18 weeks

    Sperm DNA fragmentation evaluation

Study contacts

Contact information is provided by the study sponsor or research team.

Carmelo Gusmano, MD

CONTACT

[email protected]

+393891136444

Sponsors and collaborators

Lead sponsor

IBSA Farmaceutici Italia Srl

Industry

Collaborators

  • Informapro Srl
  • University of Catania

Registry information

Official study title

Single-centre, Prospective, Randomized, Placebo-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of a Food Supplement Based on Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jan 5, 2024
Registry last updated
Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.